Talk

A conversation with Alan Topin, President of Topin & Associates, about what he has called the 'Doctor-Patient Disconnect' and the role of pharmaceutical marketers in overcoming that disconnect by facilitating the conversation. Topin will also be a member of a panel moderated by PharmaGuy at the Social Media for Pharma conference. The panel is titled 'Getting To The Heart Of What Patients And HCPs Really Want And Need To Win Trust And Help Bridge The Widening Gap Between Patient And Prescriber.'

A conversation with Domenico Tassone, Vice-President of Digital Analytics & Operations at The Encima Group, about the privacy setting introduced by Google last year, which now lists referring keywords from organic search as

A discussion with Philippe Kirby, EUCAN MCM IT Director, MSD (Europe) Inc., who previews his presentation at the upcoming 5th Annual Digital Pharma Europe conference. Kirby also discusses what the near future of pharma digital marketing has in store especially regarding use of the iPad, social media, and analytics in physician detailing.

There has been an exponential growth of the role of Medical Science Liaisons (MSLs) over the last several years. Pharmaceutical companies are now strategically interfacing their MSLs with physicians all over the world. In this podcast, Yanis Saradjian, Director of Consulting at Cutting Edge Information, Inc., and Dr. Samuel Dyer, Chairman of the Board, Medical Science Liaison Society, discuss these trends. The conversation will review MSL key performance indicators, benchmarks, and resources for advancing the global MSL profession.

Twitter just announced a complex, confusing, and developer-alienating system that restricts their once-open, always cherished but now apparently taken for granted API. The new rules change the playing field for third party developers, establish caps on number of users, and shift guidelines to requirements across four categories of businesses. Will these new API restrictions curtail growth of health-related third-party apps and, if so, will that ultimately be

Exploring the new commercial model based on 'informed,' data-driven relationship marketing and technology. A conversation with Bob Harrell, VP of Marketing at Appature. Bob discusses the transformation currently underway in the pharma commercial model, as well as his company's

A conversation with Douglas Elwood, MD, MBA, Director, GMI Strategy and Innovation at Bristol-Myers Squibb, about one of the country's first and largest studies examining the utility of using iPads and other mobile devices in a real-time clinical setting, gathering insights on multiple variables associated with overall usage, app/website preferences, and aspects of daily clinical decision making and interactions.

A conversation with Susan Nicholas, MD, MBA, Founder and CEO of DocPons, about how her company enables healthcare providers to render services to the uninsured, underinsured, or those with caps on their existing coverage.

A conversation with Susan Collins, MS, CHES, RD, Senior Vice President, Health Education Research and Development, HealthEd, about the SurroundHealth online community of 'Healthcare Extenders.' We will focus on how this group of healthcare professionals impacts health care, why they should not be ignored by pharma marketers and how to measure ROI when working with them.

A conversation with Christopher Wooden, Vice President, Global Sales at Cegedim Strategic Data (CSD), about CSD's desk research that tabulated how the top 100 pharmaceutical companies rank in terms of their Social media exposure (likes, posts, tweets, followers) on two of the most important social network websites: Facebook and Twitter.